[account_shop_links]
The Sunshine Act: Impact on US Physician Behavior
$4,900.00 – $9,800.00
Licensing Options
- SINGLE-USER LICENSE
A Single-User License allows access to an individual user.
- ENTERPRISE-WIDE LICENSE
An Enterprise-Wide License allows access to all employees and sites within an organization.
Report Overview
The Sunshine Act has been finalized. The data have been (and are being) collected. The figures are being tallied. The key question for pharma is, and may be for some time, “How significant is this impact?”
In this report, ISR asks physicians across five specialties (Cardiology, CNS / Neurology, Oncology, Primary Care, Respiratory / Pulmonology) to assess the impact that the Sunshine Act has had on their practice now that it has been implemented. Building on data collected two years ago in ISR’s The Sunshine Act: Pharma Impact – Changes in US Physician Behavior, this new edition explores physicians’ evolving concerns with the Sunshine Act.
What you will learn:
- How participation in various interactions with pharma has changed since implementation of the Sunshine Act
- Rationale for why the Sunshine Act is negatively impacting some practices
- The most valuable and effective channels of information
- Preferred delivery methods for different types of information
- Which pharmaceutical companies have the most effective sales teams and which have the best online / e-Detailing presentations
Methodology:
ISR conducted 20-minute web-based surveys with 173 U.S.-based, board-certified physicians. Respondents have an average of 17 years of experience and see an average of 105 patients per week.
- Cardiology prescribers: 30
- CNS/Neurology prescribers: 32
- Oncology prescribers: 32
- Primary Care prescribers: 48
- Respiratory/Pulmonology prescribers: 31
